{"log_id": 6119672209725410388, "direction": 0, "words_result_num": 99, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998333, "min": 0.995315}, "location": {"width": 233, "top": 52, "height": 39, "left": 936}, "words": "2007年4月25日"}, {"probability": {"variance": 0.000288, "average": 0.987487, "min": 0.963468}, "location": {"width": 73, "top": 98, "height": 33, "left": 1085}, "words": "5-3"}, {"probability": {"variance": 3.4e-05, "average": 0.993102, "min": 0.984505}, "location": {"width": 80, "top": 129, "height": 19, "left": 190}, "words": "【老年用药"}, {"probability": {"variance": 0.000188, "average": 0.99265, "min": 0.939337}, "location": {"width": 748, "top": 139, "height": 30, "left": 220}, "words": "般来说,由于老年患者肝、肾或心脏功能减低,以及合并其他疾病或药物治疗,所以对老年患者选择剂量时"}, {"probability": {"variance": 0, "average": 0.980059, "min": 0.980059}, "location": {"width": 16, "top": 142, "height": 18, "left": 1114}, "words": "剂"}, {"probability": {"variance": 0.000241, "average": 0.993276, "min": 0.952401}, "location": {"width": 140, "top": 168, "height": 22, "left": 200}, "words": "范围的最低点开始"}, {"probability": {"variance": 8e-06, "average": 0.996459, "min": 0.991972}, "location": {"width": 104, "top": 190, "height": 19, "left": 203}, "words": "药物相互作用】"}, {"probability": {"variance": 0.01596, "average": 0.952561, "min": 0.414836}, "location": {"width": 583, "top": 200, "height": 32, "left": 204}, "words": "地丹诺辛:在口服本品前2小时或同时服用地丹诺辛,可使地丹诺辛稳态AUCu-1增加"}, {"probability": {"variance": 0.034894, "average": 0.898942, "min": 0.43202}, "location": {"width": 269, "top": 202, "height": 19, "left": 846}, "words": "1%。在口服本品前2小时服用地丹诺"}, {"probability": {"variance": 0.004515, "average": 0.963009, "min": 0.765973}, "location": {"width": 183, "top": 232, "height": 19, "left": 195}, "words": "更昔洛韦的稳态AUC下降21"}, {"probability": {"variance": 0.00188, "average": 0.984508, "min": 0.759003}, "location": {"width": 567, "top": 222, "height": 25, "left": 444}, "words": "但两药同时使用时更昔洛韦的AUC不受影响。两种药物的肾清除率均没有显著改变"}, {"probability": {"variance": 0.007425, "average": 0.969255, "min": 0.65426}, "location": {"width": 215, "top": 251, "height": 21, "left": 203}, "words": "齐多天定:当口服本品每次100"}, {"probability": {"variance": 0.003941, "average": 0.974871, "min": 0.693661}, "location": {"width": 664, "top": 244, "height": 22, "left": 463}, "words": "每8小时1次和齐多夫定每次100mg,每4小时1次时,更昔洛韦的平均稳态AUC下降17±25%,齐"}, {"probability": {"variance": 0.008587, "average": 0.950994, "min": 0.675322}, "location": {"width": 153, "top": 273, "height": 19, "left": 197}, "words": "多夫定稳态AUC0-4增加"}, {"probability": {"variance": 0.004472, "average": 0.979106, "min": 0.563582}, "location": {"width": 727, "top": 265, "height": 24, "left": 398}, "words": "%。由于齐多夫定与更昔洛韦均有可能引起中性粒细胞减少和贫血,些患者可能不能耐受两种药物的全"}, {"probability": {"variance": 0.000247, "average": 0.990406, "min": 0.959094}, "location": {"width": 80, "top": 294, "height": 20, "left": 197}, "words": "量联合使用"}, {"probability": {"variance": 1.6e-05, "average": 0.996645, "min": 0.989257}, "location": {"width": 180, "top": 312, "height": 25, "left": 202}, "words": "丙磺舒:当口服本品每次"}, {"probability": {"variance": 0.003056, "average": 0.980257, "min": 0.797573}, "location": {"width": 172, "top": 309, "height": 20, "left": 447}, "words": "每8小时1次和丙磺舒每次"}, {"probability": {"variance": 0.028912, "average": 0.908195, "min": 0.377066}, "location": {"width": 444, "top": 306, "height": 20, "left": 675}, "words": "每6小时1次时,更营洛韦的平均稳态AUC08增加53±91%,肾清"}, {"probability": {"variance": 0.011674, "average": 0.960454, "min": 0.529147}, "location": {"width": 383, "top": 330, "height": 28, "left": 195}, "words": "率降低22±20%,这种相互作用与竞争肾小管分泌有关"}, {"probability": {"variance": 0.001692, "average": 0.982564, "min": 0.782173}, "location": {"width": 905, "top": 347, "height": 32, "left": 202}, "words": "亚胺培南一西司他丁:同时接受本品和亚胺培南一西司他丁的患者有出现无显著特点的癫痫发作的报道,故除非潜在获益超过风险"}, {"probability": {"variance": 1e-06, "average": 0.999388, "min": 0.996225}, "location": {"width": 162, "top": 376, "height": 22, "left": 195}, "words": "这些药物不可同时使用"}, {"probability": {"variance": 0.005822, "average": 0.977589, "min": 0.541986}, "location": {"width": 909, "top": 387, "height": 34, "left": 202}, "words": "其他药物:抑制快速分裂细胞群如骨髓、精原细胞、皮肤生发层和胃肠道粘膜细胞复制的药物与更昔洛韦合用均可增加毒性。因此"}, {"probability": {"variance": 0.010447, "average": 0.949565, "min": 0.466931}, "location": {"width": 929, "top": 406, "height": 35, "left": 200}, "words": "此类药物如氨苯砜、戊烷脒、5一氟胞嘧啶、长春新碱、长春碱、阿霉索、二性霉素B、甲氧苄氨嘧啶/磺胺甲基异嗯唑复合物或其他核"}, {"probability": {"variance": 0.004639, "average": 0.982007, "min": 0.663198}, "location": {"width": 365, "top": 434, "height": 26, "left": 195}, "words": "苷类似物仅可在潜在获益超过风险时与本品同时使用"}, {"probability": {"variance": 1e-06, "average": 0.998998, "min": 0.997084}, "location": {"width": 75, "top": 461, "height": 17, "left": 202}, "words": "药物过量】"}, {"probability": {"variance": 0.001068, "average": 0.982035, "min": 0.866523}, "location": {"width": 255, "top": 474, "height": 28, "left": 204}, "words": "未见口服本品过量的报道。剂量高达"}, {"probability": {"variance": 2e-06, "average": 0.998319, "min": 0.997217}, "location": {"width": 77, "top": 474, "height": 21, "left": 521}, "words": "天时,一次"}, {"probability": {"variance": 1.1e-05, "average": 0.997373, "min": 0.990318}, "location": {"width": 90, "top": 472, "height": 19, "left": 678}, "words": "天6次或一次"}, {"probability": {"variance": 0.00607, "average": 0.961126, "min": 0.6906}, "location": {"width": 281, "top": 468, "height": 24, "left": 845}, "words": "天3次,除发生短暂性白细胞减少外,未"}, {"probability": {"variance": 8e-05, "average": 0.994205, "min": 0.97402}, "location": {"width": 112, "top": 500, "height": 20, "left": 197}, "words": "见其他毒副作用"}, {"probability": {"variance": 0.005821, "average": 0.979805, "min": 0.526986}, "location": {"width": 606, "top": 510, "height": 31, "left": 203}, "words": "对于用药过量患者,透析和水化能降低药物血浆浓度。必要时可考虑使用造血生长因子"}, {"probability": {"variance": 8.2e-05, "average": 0.99155, "min": 0.974372}, "location": {"width": 78, "top": 541, "height": 19, "left": 201}, "words": "药理毒理】"}, {"probability": {"variance": 3e-06, "average": 0.997616, "min": 0.995641}, "location": {"width": 65, "top": 562, "height": 19, "left": 203}, "words": "药理作用"}, {"probability": {"variance": 0.008027, "average": 0.968772, "min": 0.449372}, "location": {"width": 924, "top": 570, "height": 35, "left": 201}, "words": "本品为一种2一脱氧鸟嘌呤核苷的类似物,可抑制疱疹病毒的复制。其作用机理是:更营洛韦首先被巨细胞病毒(CMV)编码的蛋白"}, {"probability": {"variance": 0.005315, "average": 0.975425, "min": 0.623092}, "location": {"width": 744, "top": 592, "height": 30, "left": 193}, "words": "激酶同系物磷酸化成单磷酸盐,再通过细胞激酶一步磷酸化成二磷酸盐和三磷酸盐。在CMV感染的细胞内"}, {"probability": {"variance": 0.003276, "average": 0.978017, "min": 0.806606}, "location": {"width": 158, "top": 593, "height": 17, "left": 965}, "words": "磷酸盐的水平比非感染"}, {"probability": {"variance": 0.01126, "average": 0.966248, "min": 0.469264}, "location": {"width": 418, "top": 614, "height": 30, "left": 195}, "words": "细胞中的水平高100倍,提示本品在感染的细胞中可优先磷商"}, {"probability": {"variance": 0.011524, "average": 0.951724, "min": 0.58664}, "location": {"width": 389, "top": 612, "height": 21, "left": 734}, "words": "旦形成三磷酸盐,能在CMV感染的细胞内持续数天。更昔"}, {"probability": {"variance": 0.002702, "average": 0.985716, "min": 0.765395}, "location": {"width": 307, "top": 638, "height": 25, "left": 195}, "words": "洛韦的三磷酸盐能通过以下方式抑制病毒的"}, {"probability": {"variance": 0.026421, "average": 0.916872, "min": 0.39262}, "location": {"width": 580, "top": 633, "height": 24, "left": 544}, "words": "成:1竞争性抑制病MA聚合酶;2)共同进入病毒DNA内,从而导致病毒DNA延"}, {"probability": {"variance": 1.5e-05, "average": 0.997446, "min": 0.990832}, "location": {"width": 58, "top": 662, "height": 18, "left": 198}, "words": "长的终止"}, {"probability": {"variance": 0.002607, "average": 0.970481, "min": 0.809743}, "location": {"width": 312, "top": 677, "height": 26, "left": 202}, "words": "临床已证实:更昔洛韦对CMV和单纯疱疹病毒"}, {"probability": {"variance": 0.064295, "average": 0.834793, "min": 0.37543}, "location": {"width": 183, "top": 676, "height": 32, "left": 564}, "words": "致的感染有效"}, {"probability": {"variance": 3e-06, "average": 0.998454, "min": 0.996154}, "location": {"width": 52, "top": 704, "height": 17, "left": 215}, "words": "理研究"}, {"probability": {"variance": 0.005346, "average": 0.966587, "min": 0.62799}, "location": {"width": 439, "top": 715, "height": 30, "left": 202}, "words": "遗传毒性:本品Ames试验结果阴性。体外试验中,更洛韦可"}, {"probability": {"variance": 0.011863, "average": 0.952812, "min": 0.518246}, "location": {"width": 435, "top": 712, "height": 24, "left": 684}, "words": "鼠淋巴痛细胞的突变和人淋巴细胞DNA的损伤。在小鼠微核试验"}, {"probability": {"variance": 0.011004, "average": 0.95409, "min": 0.57676}, "location": {"width": 423, "top": 735, "height": 32, "left": 196}, "words": "中,更昔洛韦静脉注射给药量相当于临床暴露量的28至倍"}, {"probability": {"variance": 0.010556, "average": 0.960757, "min": 0.533384}, "location": {"width": 341, "top": 734, "height": 22, "left": 656}, "words": "裂变作用,但在与临床暴露量相当时无此作用"}, {"probability": {"variance": 0.008297, "average": 0.964978, "min": 0.402774}, "location": {"width": 911, "top": 753, "height": 33, "left": 202}, "words": "生殖毒性:雌性小鼠静脉给予更洛韦的暴露量约为临露量的1.7倍时,可引起交配行为减少,生育能力减低,并增加胚胎死"}, {"probability": {"variance": 0.00813, "average": 0.967271, "min": 0.612134}, "location": {"width": 726, "top": 774, "height": 33, "left": 194}, "words": "率。每日口服或静脉给予本品0.2-10mg/kg时,可引起雄性小商力下降,并降低小鼠和狗的生精能力"}, {"probability": {"variance": 0.012776, "average": 0.961001, "min": 0.540187}, "location": {"width": 369, "top": 798, "height": 28, "left": 203}, "words": "更昔洛韦静脉给药,对家兔和小鼠均显示有胚胎毒性"}, {"probability": {"variance": 0.007154, "average": 0.959875, "min": 0.66781}, "location": {"width": 496, "top": 796, "height": 22, "left": 623}, "words": "家有致畸作用。在相当于2倍临床暴露量下,至少85%的家兔和小鼠出"}, {"probability": {"variance": 0.00055, "average": 0.984818, "min": 0.901296}, "location": {"width": 403, "top": 819, "height": 27, "left": 195}, "words": "现胚胎重吸收。在家兔观察到的作用包括:胚胎生长迟缓"}, {"probability": {"variance": 0.013999, "average": 0.947536, "min": 0.447449}, "location": {"width": 429, "top": 817, "height": 20, "left": 690}, "words": "畸和/或母体毒性。致畸作用包括:上颚裂,无眼畸形/小眼"}, {"probability": {"variance": 0.001353, "average": 0.983077, "min": 0.817283}, "location": {"width": 662, "top": 835, "height": 32, "left": 195}, "words": "畸形,器官发育不全(肾和胰腺),脑积水和短颌。在小鼠,可观察到母体/胚胎毒性和胚胎死亡"}, {"probability": {"variance": 0.006041, "average": 0.981365, "min": 0.410909}, "location": {"width": 916, "top": 856, "height": 29, "left": 207}, "words": "性小鼠在交配前、孕期和授乳期,每日静脉给予更昔洛韦(相当于临床暴露量的1.7倍),可引起达1月龄的雄性动物后代丸和精"}, {"probability": {"variance": 0.000221, "average": 0.991758, "min": 0.948363}, "location": {"width": 291, "top": 881, "height": 26, "left": 195}, "words": "囊发育不全,以及胃的非腺体区病理改变"}, {"probability": {"variance": 0.011644, "average": 0.966946, "min": 0.400146}, "location": {"width": 692, "top": 896, "height": 31, "left": 208}, "words": "政癌性:小鼠长期(18个月)经口给予更洛韦剂量为20和1000mg/kg/日时,有致癌作用。当剂量为"}, {"probability": {"variance": 0.00052, "average": 0.98672, "min": 0.916886}, "location": {"width": 170, "top": 898, "height": 20, "left": 952}, "words": "kg/日时,显著增加雄性"}, {"probability": {"variance": 0.003188, "average": 0.978203, "min": 0.64364}, "location": {"width": 927, "top": 915, "height": 32, "left": 196}, "words": "小鼠包皮腺、雄性和雌性小鼠前胃(非腺性粘膜)、雌性小鼠生殖组织(卵巢,子宫,乳腺:阴蒂腺和阴道)及肝脏的肿瘤发生率。当"}, {"probability": {"variance": 0.008581, "average": 0.965847, "min": 0.532928}, "location": {"width": 929, "top": 938, "height": 32, "left": 195}, "words": "剂量为20mg/kg/月时,轻度增加雄性小鼠包皮腺和副泪腺、雄性和雌性小鼠的前胃和雌性小鼠肝脏的肿瘤发生。当小鼠服用更背洛"}, {"probability": {"variance": 4.1e-05, "average": 0.99624, "min": 0.97623}, "location": {"width": 296, "top": 965, "height": 24, "left": 196}, "words": "韦剂量为1mg/kg/日时,未观察到致癌作用"}, {"probability": {"variance": 1.2e-05, "average": 0.996302, "min": 0.989684}, "location": {"width": 87, "top": 989, "height": 19, "left": 202}, "words": "药代动力学"}, {"probability": {"variance": 0.016488, "average": 0.963088, "min": 0.368343}, "location": {"width": 921, "top": 1000, "height": 30, "left": 202}, "words": "吸收:在饥饿状态下口服更昔洛韦的绝对生物利用度大约为5%,进食后为6%至9%当进餐时口服更洛剂量3g/日(500mg每3小"}, {"probability": {"variance": 0.000531, "average": 0.988684, "min": 0.881257}, "location": {"width": 700, "top": 1020, "height": 31, "left": 194}, "words": "时一次,每日6次和1000mg每日3次),用24小时血清浓度时间曲线下面积(AUC)和最大血清浓度(C"}, {"probability": {"variance": 0.006622, "average": 0.949592, "min": 0.7288}, "location": {"width": 187, "top": 1022, "height": 20, "left": 931}, "words": "测定稳态吸收程度,两种服"}, {"probability": {"variance": 0.008518, "average": 0.964462, "min": 0.48986}, "location": {"width": 397, "top": 1045, "height": 27, "left": 195}, "words": "用方法得到的结果相似,分别为AUC-215.9±4.2和15.4±"}, {"probability": {"variance": 0.001823, "average": 0.978602, "min": 0.794247}, "location": {"width": 235, "top": 1045, "height": 19, "left": 748}, "words": "x1.02±0.24和1.18±0.36μg/ml"}, {"probability": {"variance": 0.001647, "average": 0.982969, "min": 0.760181}, "location": {"width": 919, "top": 1063, "height": 29, "left": 201}, "words": "分布:静脉给药后,更昔洛韦稳态分布容积为0.74±0.15L/kg口服制剂,未观察到AUC和用药者体重(范围:55至128kg)之间的相"}, {"probability": {"variance": 0.006455, "average": 0.969745, "min": 0.574566}, "location": {"width": 693, "top": 1083, "height": 29, "left": 200}, "words": "关性,不需根据体重确定口服剂量。在更昔洛韦度为0.5至51μg/ml下,血浆蛋白结合率为1%至2"}, {"probability": {"variance": 0.022459, "average": 0.932609, "min": 0.421562}, "location": {"width": 244, "top": 1109, "height": 21, "left": 204}, "words": "代谢:单次口服C标记的更昔洛韦"}, {"probability": {"variance": 0.000603, "average": 0.989222, "min": 0.8665}, "location": {"width": 624, "top": 1105, "height": 21, "left": 497}, "words": "后,86±3%的服用量经粪便排泄,5±1%经尿液排泄。尿液和粪便内得到的代谢产物的放"}, {"probability": {"variance": 3.9e-05, "average": 0.996746, "min": 0.978483}, "location": {"width": 139, "top": 1133, "height": 18, "left": 194}, "words": "射性不超过1%和2%"}, {"probability": {"variance": 0.001439, "average": 0.983344, "min": 0.764371}, "location": {"width": 904, "top": 1144, "height": 30, "left": 202}, "words": "清除:口服时,日总剂量4g呈线形动力学。更昔洛韦的主要排泄途径是通过肾小球滤过和主动的肾小管分泌以原型药物经肾脏排泌"}, {"probability": {"variance": 0.009083, "average": 0.960499, "min": 0.557526}, "location": {"width": 502, "top": 1167, "height": 27, "left": 195}, "words": "口服更昔洛韦后,在24小时内达到稳态。口服后肾脏清除率为3.1±1.2m"}, {"probability": {"variance": 6.4e-05, "average": 0.995056, "min": 0.972432}, "location": {"width": 237, "top": 1168, "height": 18, "left": 773}, "words": "口服给药后半衰期为4.8±0.9小时"}, {"probability": {"variance": 1e-06, "average": 0.998792, "min": 0.997386}, "location": {"width": 65, "top": 1195, "height": 17, "left": 202}, "words": "特殊人群"}, {"probability": {"variance": 0.006204, "average": 0.967774, "min": 0.572518}, "location": {"width": 919, "top": 1205, "height": 30, "left": 202}, "words": "肾脏损害:44例实体器官移植受体或HIY阳性患者口服本品后,随着肾功能下降,出现更昔洛韦清除率明显降低和 auco-%增加。因"}, {"probability": {"variance": 0.014647, "average": 0.959597, "min": 0.370178}, "location": {"width": 664, "top": 1227, "height": 28, "left": 194}, "words": "此,有必要对肾功能不全患者调整更昔洛韦的剂量。血液透析可使更洛韦的血浆浓度降低50%"}, {"probability": {"variance": 0.00452, "average": 0.95877, "min": 0.826386}, "location": {"width": 181, "top": 1253, "height": 22, "left": 201}, "words": "种族和性别:每次口服10"}, {"probability": {"variance": 0.000188, "average": 0.991648, "min": 0.939119}, "location": {"width": 464, "top": 1250, "height": 20, "left": 428}, "words": "每8小时一次,显示黑种人(16%)和西班牙裔(20%)患者的稳态"}, {"probability": {"variance": 0.03212, "average": 0.887808, "min": 0.392311}, "location": {"width": 142, "top": 1249, "height": 20, "left": 979}, "words": "与白种人相比,较"}, {"probability": {"variance": 9.5e-05, "average": 0.993265, "min": 0.967438}, "location": {"width": 367, "top": 1273, "height": 22, "left": 194}, "words": "低的趋势。未观察到男性和女性(12%)之间的差异"}, {"probability": {"variance": 3e-06, "average": 0.998295, "min": 0.994113}, "location": {"width": 115, "top": 1296, "height": 19, "left": 197}, "words": "贮藏】密封保存"}, {"probability": {"variance": 0.010305, "average": 0.961513, "min": 0.406429}, "location": {"width": 558, "top": 1310, "height": 28, "left": 202}, "words": "包装】聚烯烃药用塑料瓶,60粒/瓶,36粒/瓶,24/瓶,18粒/瓶,12粒/瓶,6粒/瓶"}, {"probability": {"variance": 1.9e-05, "average": 0.997121, "min": 0.985056}, "location": {"width": 145, "top": 1338, "height": 18, "left": 201}, "words": "有效期】暂定24个月"}, {"probability": {"variance": 0.00717, "average": 0.961504, "min": 0.7025}, "location": {"width": 169, "top": 1357, "height": 20, "left": 199}, "words": "执行标准】YBH4312003"}, {"probability": {"variance": 0.000827, "average": 0.979868, "min": 0.912602}, "location": {"width": 144, "top": 1380, "height": 17, "left": 202}, "words": "批准文号】国药准字"}, {"probability": {"variance": 0, "average": 0.999382, "min": 0.998397}, "location": {"width": 69, "top": 1400, "height": 16, "left": 192}, "words": "【生产企业"}, {"probability": {"variance": 7e-06, "average": 0.998383, "min": 0.990027}, "location": {"width": 272, "top": 1415, "height": 25, "left": 202}, "words": "企业名称:湖北科益药业股份有限公司"}, {"probability": {"variance": 0.001, "average": 0.991884, "min": 0.847192}, "location": {"width": 351, "top": 1434, "height": 27, "left": 202}, "words": "生产地址:湖北省葛店经济技术开发区科益工业园"}, {"probability": {"variance": 0.007094, "average": 0.975682, "min": 0.570769}, "location": {"width": 372, "top": 1456, "height": 25, "left": 203}, "words": "注册地址:武汉市东湖新技术开发区关东工业园3-3号"}, {"probability": {"variance": 2e-06, "average": 0.996455, "min": 0.994487}, "location": {"width": 66, "top": 1480, "height": 24, "left": 202}, "words": "邮政编码"}, {"probability": {"variance": 0.025425, "average": 0.896938, "min": 0.580451}, "location": {"width": 178, "top": 1493, "height": 27, "left": 198}, "words": "电话号码:028-8756125"}, {"probability": {"variance": 5e-06, "average": 0.998341, "min": 0.992867}, "location": {"width": 98, "top": 1523, "height": 19, "left": 202}, "words": "传真号码:02"}, {"probability": {"variance": 2e-06, "average": 0.997338, "min": 0.99538}, "location": {"width": 20, "top": 1522, "height": 17, "left": 355}, "words": "252"}, {"probability": {"variance": 0, "average": 0.999613, "min": 0.999613}, "location": {"width": 17, "top": 1546, "height": 17, "left": 249}, "words": "址"}, {"probability": {"variance": 0.028361, "average": 0.844318, "min": 0.381901}, "location": {"width": 456, "top": 1626, "height": 54, "left": 477}, "words": "成早尺:140210mm"}], "language": 3}